Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hPAM4-SN-38
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
hPAM4-SN-38 (IMMU-134) is an antibody-drug conjugate (ADC) developed by Immunomedics for the treatment of MUC1-expressing cancers, particularly pancreatic cancer. It consists of the humanized monoclonal antibody hPAM4 (clivatuzumab), which targets a specific epitope of Mucin 1 (MUC1), conjugated to the cytotoxic payload SN-38 (the active metabolite of irinotecan) via a CL2A linker. The mechanism of action involves the binding of the antibody to MUC1 on the surface of cancer cells, followed by internalization and release of SN-38. SN-38 then inhibits DNA Topoisomerase I, leading to double-strand DNA breaks and apoptosis. Preclinical studies have demonstrated efficacy in pancreatic cancer xenograft models.
- Other names
- clivatuzumab-SN-38clivatuzumab-SN38clivatuzumab-SN 38
02
Targets
TOP1 (DNA Topoisomerase I)Mucin 1 (MUC1), tumor-associated PAM4 epitope
Beyond the preview
Go deeper on hPAM4-SN-38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hPAM4-SN-38.